Recor Medical's Innovations Transform Hypertension Treatment Options

Recor Medical's Commitment to Hypertension Management

Recor Medical, Inc. has made a significant impact in the field of hypertension treatment with its innovative Paradise Ultrasound Renal Denervation (uRDN) System. This technology is designed to offer advanced solutions to patients suffering from resistant or uncontrolled hypertension. Recently, the American Heart Association (AHA) and American College of Cardiology (ACC) recognized the importance of renal denervation as a valuable treatment option in their updated guidelines, marking a progressive step forward in how hypertension is understood and managed.

Understanding the AHA and ACC Guidelines

In their updated guidelines, the AHA and ACC emphasize renal denervation (RDN) as a therapeutic avenue for patients who find it challenging to manage their high blood pressure with standard medications. This acknowledgment is pivotal, merging the latest research data with real-world applications, thereby guiding healthcare professionals in their treatment strategies.

Clinical Validation and Safety of RDN

The inclusion of RDN in these guidelines is not arbitrary; it stems from thorough evaluations of randomized and sham-controlled clinical trials that span diverse patient populations. These studies confirm RDN's role in hypertension management, giving healthcare providers a solid basis for incorporating this method into their clinical practice.

Reactions from Recor Medical Leadership

Lara Barghout, the President and CEO of Recor, expressed her enthusiasm regarding the guidelines. "The recognition from the AHA and ACC fortifies our mission to support cardiovascular health through innovative therapies. Our RADIANCE Global Program lays the groundwork for integrating RDN into everyday care for patients with challenging hypertension," she stated. The program has yielded substantial clinical evidence regarding the effectiveness and safety of the Paradise uRDN System.

About the Paradise uRDN System

The Paradise uRDN System stands out as the pioneering FDA-approved technology utilizing ultrasound to address hypertension. Its design focuses on reducing blood pressure by effectively disrupting overactive nerve pathways around the renal arteries. Providing ultrasound energy in a controlled manner ensures patient safety, with the HydroCooling™ system protecting the renal artery wall during treatment.

Results from the RADIANCE Global Program

Recor has actively championed the development of the Paradise system since 2009. The company’s commitment to research is evidenced by the success of three major trials: RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO. Over 500 patients participated in these studies, all achieving their primary efficacy endpoints without compromising safety.

Long-term Studies for Continuous Improvement

In a bid to build on its achievements, Recor launched the U.S. Global Paradise System (GPS) Post-Approval Study, which aims to gather extensive real-world evidence, enrolling 1,000 patients with uncontrolled hypertension. These initiatives reflect Recor's dedication to advancing hypertension management practices continually.

Transforming Hypertension Treatment Worldwide

Headquartered in Palo Alto, California, Recor Medical is a subsidiary of Otsuka Medical Devices Co., Ltd., focused on revolutionizing hypertension treatment. The Paradise uRDN system is FDA-approved and CE marked, facilitating its distribution in markets aligned with regulatory standards. By providing clinicians with advanced tools and patients with innovative treatment options, Recor Medical is set to make waves in cardiovascular health.

Contact Information

For general inquiries, you can reach out to Media Contact Lisa Owens at The Mullings Group. Interested parties can contact her via email at lowens@mullingsgroup.com or call +1-210-601-6647 for more details.

Frequently Asked Questions

What is the Paradise Ultrasound Renal Denervation System?

The Paradise uRDN System is a cutting-edge technology designed to reduce blood pressure by targeting overactive nerves around the renal arteries using ultrasound.

Why is the AHA and ACC's recognition of RDN important?

This recognition integrates the latest research and clinical findings, solidifying RDN's role as a viable option in hypertension management.

How does the Paradise uRDN System work?

The system delivers ultrasound energy in precise doses to disrupt nerve signals that contribute to high blood pressure, helping patients achieve better control.

What clinical trials support the effectiveness of the Paradise system?

Three major trials, including RADIANCE II and RADIANCE-HTN TRIO, demonstrate its efficacy and safety in managing hypertension in a variety of patient populations.

How can patients learn more about the Paradise system?

Patients interested in learning more about the Paradise system can visit Recor Medical's official website for comprehensive information and resources.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.